• Mashup Score: 2
    Question of the Week - 7 month(s) ago

    I just took the NEJM Knowledge+ Question of the Week. Test yourself: https://knowledgeplus.nejm.org/question-of-week/

    Source: knowledgeplus.nejm.org
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of nejmkplus
      nejmkplus

      A 37-year-old woman presents for follow-up evaluation of a kidney stone that was first detected by ultrasound 2 months ago when she presented to the emergency department with abdominal pain and hematuria after spending a . . . #MedTwitter #MedEducation https://t.co/kU7QqlZlDF https://t.co/AsAPYYmlyB

  • Mashup Score: 0
    Clive Peedell (@clivepeedell) on Threads - 10 month(s) ago

    Consultant Clinical Oncologist. Politics/medical politics. #NHS campaigner. BTOG and UK SABR Consortium steering committee member. Views are personal. 64 Followers.

    Source: Threads
    Categories: Latest Headlines, Oncologists2
    Tweet Tweets with this article
    • Profile photo of cpeedell
      cpeedell

      At some point I would love to delete Twitter and move to #Threads permanently. It’s going to take some transition time, because I use Twitter for #MedEducation purposes. Please follow the trend to move though #Medtwitter #Radonc #Medonc #Lcsm #Pcsm #nhs https://t.co/MqPhedmbn9

  • Mashup Score: 0
    FDA grants fast track designation to sapanisertib for lung cancer subset - 2 year(s) ago

    The FDA granted fast track designation to sapanisertib for treatment of certain patients with non-small cell lung cancer.The designation applies to use of the agent for adults with unresectable or metastatic squamous NSCLC whose tumors harbor nuclear factor erythroid 2-related factor (NRF2) mutations and who have received prior immune checkpoint inhibitor therapy and platinum-based chemotherapy.

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      .@US_FDA grants fast-track designation to #sapanisertib for lung cancer subset. https://t.co/qX0pQJDGG4 #lungcancer #nonsmallcelllungcancer #MedTwitter #MedEd #MedEducation #Oncology #OncAlert

  • Mashup Score: 0
    Avoid capital gains taxes like a billionaire using ‘buy, borrow, die’ strategy - 2 year(s) ago

    Often, after speaking about taxes at a medical conference, we are approached by a physician attendee who has read that billionaires, like Warren Buffet and Elon Musk, pay less taxes than they do and they wonder how that can be.Typically, the physician then asks how they can do what the super-rich do in this regard. In this article, we examine the “buy, borrow, die” strategy that

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      Avoid capital gains taxes like a billionaire using ‘buy, borrow, die’ strategy. https://t.co/YGxJDc9CKg #MedTwitter #MedEd #Oncology #Hematology #HemOnc #MedEducation #taxes #investment #financialmanagement

  • Mashup Score: 3
    Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer - 2 year(s) ago

    The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed. An analysis of the randomized study presented at ESMO Congress revealed a high rate of therapy discontinuation due to treatment-related adverse events, the investigators noted.

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      #Immunotherapy combo fails to extend disease-free survival in high-risk #kidneycancer. https://t.co/sRSBB7IJpZ #ESMO2022 @ESMO @MemorialSloanKetteringCancerCenter #highriskkidneycancer #diseasefreesurvival #MedTwitter #MedEd #MedEducation #Oncology #OncAlert

  • Mashup Score: 0
    The next best thing to cloning - 2 year(s) ago

    Blogs | | It’s incredible how many ways the world has changed since the pandemic. For those of us in eye care practices, the shortage of qualified, willing people to work in our offices has been maybe the hardest part to manage. Many of us have turned to hiring people with no medical office experience. “Hire for attitude, train for skills” has always been our mantra, but we don’t

    Source: www.healio.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of Healio_OSN
      Healio_OSN

      The next best thing to #cloning. https://t.co/5OFN9F73Ax #practicemanagement @Alchemy Vision #NewHires #Training #MedEd #MedEducation #Ocular #Opthalmology

  • Mashup Score: 0
    Daratumumab improves response among younger patients with acute lymphoblastic leukemia - 2 year(s) ago

    CHICAGO — The addition of daratumumab to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia, study results showed.Data from the phase 2 DELPHINUS trial presented at ASCO Annual Meeting suggest the addition of daratumumab (Darzalex, Janssen) — a CD38-directed monoclonal antibody — to a standard chemotherapy

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      #ChildhoodCancerAwarenessMonth Adding #daratumumab (Darzalex, @JanssenUS) to #chemotherapy improved outcomes for younger cancer patients. https://t.co/tLEo5BDpmP #leukemia #acutelymphoblasticleukemia @MoffittResearch #MedTwitter #MedEd #MedEducation #Oncology #OncAlert

  • Mashup Score: 2
    Patient anatomy, healing response greatly affect visual outcomes - 2 year(s) ago

    Ocular Surgery News | We perform a beautiful cataract surgery with the expectation that the patient will heal normally and achieve outstanding vision.While that happens the vast majority of the time, there are occasional patients in whom the visual results are not as expected. We all know to temper expectations so that patients have a realistic concept of what is possible with modern-day IOL…

    Source: www.healio.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of Healio_OSN
      Healio_OSN

      Healing response greatly affects visual outcomes https://t.co/g7hlX3ckWX #MedTwitter #MedEducation #OncularSurgery #intraocular #lenscataract #Opthalmology @devgan

Load More